AlphAIalphai — Financial news for AI agents
SEC EDGARSEP 31 min read$FDMT

Bizily Scott sold $8K of FDMT

Bizily Scott (Chief Legal Officer) sold 584 shares of 4D Molecular Therapeutics, Inc. (FDMT) at $14.00 on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bizily Scott
Published Sep 3, 2026, 10:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 11:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$FDMT
Neutral
high confidence
Mentioned
$FDMT
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FDMTNeutralLow
01

Why it matters

The filing provides a fresh, primary‑source fact but the transaction size is trivial.

02

Market read

A routine insider sale with minimal market impact.

03

What to watch

Potential upcoming corporate actions that prompted the pre‑arranged sale.

Relevance 2/10Novelty 4/10Timing: transaction dated 2026-09-01

Background

Form 4 filings disclose insider trades; investors monitor them for signals.

Company-level read

Ticker impact

$FDMTNeutralHigh confidence
Context

Chief Legal Officer Bizily Scott sold 584 shares of FDMT for $8,176 on a 10b5-1 plan.

Expected impact

No significant price movement expected.

Evidence & confidence

The sale size is small relative to total shares outstanding and follows a pre‑arranged plan.

Market effects

Sector

None; isolated insider transaction.

Regional

None; company is US‑based with limited market exposure.

Global

None

Counterpoint

What could challenge this read

Even small insider sales can signal lack of confidence, but the 10b5‑1 plan mitigates concern.

Key entities

  • person
    Bizily Scott

    Chief Legal Officer of 4D Molecular Therapeutics, Inc.

  • company
    4D Molecular Therapeutics, Inc.

    Biotech firm developing molecular therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

FDMT insider trading history →

Related articles

AUG 17
$FDMTMed

Top Biotech Gainers: FDMT, OABI, ACXP Rally On Pipeline And Regulatory News

Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.

rttnews.com7 min
AUG 13
$FDMTMed

4D Molecular Therapeutics, Inc. (FDMT): Results of Operations and Financial Condition

4D Molecular Therapeutics, Inc. (FDMT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones • Completed enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027 • 4D-150 4FRONT-1 Phase 3 topline data expected in Q2 2027 • Prese

SEC EDGAR 8-K6 min
AUG 5
$FDMTMedAI 8/10

4DMT reports new phase 2b gene therapy data for wet AMD

4D Molecular Therapeutics reported positive 2-year results from its phase 2b PRISM trial of 4D-150 for wet age-related macular degeneration. The company said the study showed sustained BCVA and OCT central subfield thickness improvements and reduced treatment burden versus projected on-label aflibercept. Safety was described as well tolerated, with 2.8% mild transient inflammation. Phase 3 topline data is expected in 2027.

glance.eyesoneyecare.com4 min
JUL 20
$FDMTMed

Why Is 4D Molecular Therapeutics Stock Gaining Monday? - 4D Molecular Therapeutics (NASDAQ:FDMT)

4D Molecular Therapeutics (FDMT) shares rose after Phase 2b results for 4D-150 in wet AMD. In 45 patients, the 3E10 vg/eye dose was chosen for Phase 3. As of May 18, 2026, it maintained visual acuity and reduced treatment burden 78% vs projected aflibercept injections, with 2.8% mild inflammation. Phase 3 enrollment completed; topline expected 2027. HC Wainwright reiterated Buy, $36 target.

benzinga.com4 min